Avoid common mistakes on your manuscript.
Correction to: BioDrugs https://doi.org/10.1007/s40259-023-00636-z
Declarations section: The Funding statement that previously read
Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502).
should read
Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281).
The original article has corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Woo, H., Shin, G., Lee, D. et al. Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries. BioDrugs 38, 323 (2024). https://doi.org/10.1007/s40259-024-00645-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-024-00645-6